DLG1 is altered in 0.01% of all cancers with invasive breast carcinoma, high grade ovarian serous adenocarcinoma, neuroendocrine carcinoma, NOS, and non-small cell lung carcinoma having the greatest prevalence of alterations .
The most common alterations in DLG1 are DLG1-BRAF Fusion (0.02%), DLG1-KMT2A Fusion (0.01%), and DLG1-PIK3CA Fusion (0.04%) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.